Tickers

1. Composite Trajectory Verdict

For a pre-revenue clinical-stage biotechnology company, the cash flow statement and balance sheet carry the most weight because they determine runway and going-concern viability, while the income statement primarily reflects R&D investment intensity.

Composite Trajectory: Deteriorating

All three financial statements show consistent deterioration over the comparable periods provided. The annual net loss widened from $77.3 million (FY2024) to $79.6 million (FY2025) despite a $21.0 million impairment charge in FY2024 that did not recur (10-K FY2025, Consolidated Statements of Operations). Quarterly net losses increased year-over-year in both Q1 (from $21.2 million to $23.3 million) and Q2 (from $18.4 million to $25.3 million) (10-Q Q1 2026 and 10-Q Q2 2026, Condensed Statements of Operations). Operating cash burn increased annually (from $57.7 million to $63.5 million) and year-to-date through Q2 (from $39.8 million to $44.2 million) (10-K FY2025 and 10-Q Q2 2026, Statements of Cash Flows). Cash, cash equivalents, and marketable debt securities fell from $126.9 million at December 31, 2024 to $66.9 million at December 31, 2025 to $33.0 million at June 30, 2026 (10-K FY2025 and 10-Q Q2 2026, Balance Sheets). Stockholders' equity eroded from $120.8 million to $53.4 million to $11.4 million over the same three dates (same sources). Both the 10-K and 10-Qs explicitly state that current resources are insufficient to fund operations for 12 months and raise substantial doubt about the ability to continue as a going concern.

2. Red Flags

• Going-concern qualification in consecutive filings: The FY2025 10-K states cash as of December 31, 2025 "will not be sufficient to fund our operations over the next 12 months" and "raises substantial doubt about our ability to continue as a going concern" (10-K FY2025, Liquidity and Capital Resources). The Q1 and Q2 2026 10-Qs repeat this language with updated cash positions (10-Q Q1 2026 and 10-Q Q2 2026, Liquidity and Going Concern).
• Cash and investments declining 74% in 18 months: Cash, cash equivalents, and marketable debt securities dropped from $126.9 million (Dec 31, 2024) to $66.9 million (Dec 31, 2025) to $33.0 million (Jun 30, 2026) (10-K FY2025, Balance Sheet; 10-Q Q2 2026, Balance Sheet).
• Equity erosion of 90%: Total stockholders' equity fell from $120.8 million (Dec 31, 2024) to $53.4 million (Dec 31, 2025) to $11.4 million (Jun 30, 2026) (10-K FY2025, Balance Sheet; 10-Q Q2 2026, Balance Sheet).
• Accelerating net losses: FY2025 net loss of $79.6 million exceeded FY2024's $77.3 million; Q2 2026 net loss of $25.3 million nearly doubled Q2 2025's $18.4 million; YTD Q2 2026 net loss of $48.6 million exceeded YTD Q2 2025's $39.5 million (10-K FY2025 and 10-Q Q2 2026, Statements of Operations).
• Revenue disappeared in 2026: Quarterly revenue was $0 in both Q1 and Q2 2026 versus $2.82 million in each comparable 2025 quarter (milestone revenue from Simcere agreement) (10-Q Q1 2026 and 10-Q Q2 2026, Statements of Operations).
• Operating cash burn increasing: Net cash used in operations rose from $57.7 million (FY2024) to $63.5 million (FY2025) and from $39.8 million (YTD Q2 2025) to $44.2 million (YTD Q2 2026) (10-K FY2025 and 10-Q Q2 2026, Statements of Cash Flows).
• Private placement advance liability: $10.0 million recorded as a current liability at June 30, 2026 for proceeds received in advance of a July 2, 2026 closing (10-Q Q2 2026, Balance Sheet and Subsequent Event note).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Net losses have widened across every comparable period. The FY2025 net loss of $79.6 million exceeded FY2024's $77.3 million (10-K FY2025, Consolidated Statements of Operations). Quarter-over-quarter, Q1 2026 net loss of $23.3 million exceeded Q1 2025's $21.2 million, and Q2 2026 net loss of $25.3 million was 38% larger than Q2 2025's $18.4 million (10-Q Q1 2026 and 10-Q Q2 2026, Condensed Statements of Operations). Year-to-date through Q2, the 2026 net loss of $48.6 million exceeded the 2025 comparable period's $39.5 million (10-Q Q2 2026, Condensed Statements of Operations). Revenue declined annually from $16.1 million to $13.9 million and disappeared entirely in the first half of 2026 (10-K FY2025 and 10-Q Q2 2026, Statements of Operations). R&D expenses increased 25% annually ($58.7 million to $73.7 million) driven by MICVO manufacturing and clinical trial costs (10-K FY2025, MD&A). G&A decreased annually ($25.4 million to $22.2 million) but rose sharply in Q2 2026 to $9.9 million from $5.4 million in Q2 2025, partly due to CEO separation costs (10-Q Q2 2026, Stock-Based Compensation note).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Operating cash burn has increased in every comparable period. FY2025 operating cash outflow of $63.5 million exceeded FY2024's $57.7 million (10-K FY2025, Consolidated Statements of Cash Flows). Year-to-date through Q2, 2026 operating cash outflow of $44.2 million exceeded 2025's $39.8 million (10-Q Q2 2026, Condensed Statements of Cash Flows). Investing cash flows were positive in all periods due to net redemptions of marketable debt securities exceeding purchases, but the magnitude dropped from $58.9 million (FY2025) to $37.7 million (YTD Q2 2026) as the securities portfolio shrank (10-K FY2025 and 10-Q Q2 2026, Statements of Cash Flows). Financing cash flows collapsed from $59.3 million inflow (FY2024, driven by equity issuances) to $0.6 million (FY2025, minimal option exercises) before a $10.0 million private placement advance appeared in Q2 2026 (10-K FY2025 and 10-Q Q2 2026, Statements of Cash Flows). The net change in cash and equivalents was negative $4.1 million for FY2025 and positive $3.4 million for YTD Q2 2026 only because of the private placement advance (10-K FY2025 and 10-Q Q2 2026, Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: The balance sheet shows rapid erosion of liquidity and equity. Total cash, cash equivalents, and marketable debt securities fell from $126.9 million (Dec 31, 2024) to $66.9 million (Dec 31, 2025) to $33.0 million (Jun 30, 2026) (10-K FY2025 and 10-Q Q2 2026, Balance Sheets). Total current assets dropped from $132.4 million to $72.1 million to $36.7 million over the same dates (same sources). Total assets declined from $157.2 million to $91.5 million to $54.9 million (same sources). Total liabilities increased from $36.4 million to $38.1 million to $43.5 million, with the Q2 2026 increase driven by a $10.0 million private placement advance liability (10-Q Q2 2026, Balance Sheet). Stockholders' equity collapsed from $120.8 million to $53.4 million to $11.4 million, while the accumulated deficit grew from $363.6 million to $443.2 million to $491.8 million (10-K FY2025 and 10-Q Q2 2026, Balance Sheets). The operating lease right-of-use asset and liability have been relatively stable around $11-12 million and $17-18 million respectively (same sources).

6. Data Gaps

• Q3 2025 and Q4 2025 quarterly financial statements (only FY2025 annual and Q1/Q2 2026 quarterly data provided)
• Q3 2026 and Q4 2026 quarterly data (not yet filed)
• Full-year 2026 results (not yet complete)
• Detailed breakdown of R&D program costs for quarterly periods (only annual FY2025 MICVO vs PYX-106 split provided in 10-K MD&A)
• Terms and size of the ATM facility utilization beyond the $150 million capacity disclosed (no shares sold under ATM in FY2025 or H1 2026 per filings)